熱門資訊> 正文
Aeterna Zentaris报告第四季度业绩
2024-03-27 20:18
- Aeterna Zentaris press release (NASDAQ:AEZS): Q4 total revenue for was $0.1 million as compared to $2.5 million for the same period in 2022, representing an decrease of $2.4 million, this decrease is primarily due to a $2.5 million decrease as a result of the termination of the Company’s agreement with Novo Nordisk Healthcare in May 2023, offset by a $0.1 milling increase in product sales.
- EPS loss of $1.16
More on Aeterna Zentaris
- Seeking Alpha’s Quant Rating on Aeterna Zentaris
- Historical earnings data for Aeterna Zentaris
- Financial information for Aeterna Zentaris
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
